As Vice President, Corporate Strategy Jean-Luc works closely with the CEO and the Executive Committee at VCLS to drive the company’s mid- to long-term growth and evolution. In this role, he leads the initiative to evaluate new trends in the life sciences arena and where applicable, to translate them into new business opportunities. He is also responsible for the coordination of acquisitions and partnerships, and the identification and management of major corporate risks. Before becoming VP, Jean-Luc was responsible for creating and growing the Clinical Operations Group at VCLS.
Jean-Luc brings to the role more than 32 years of international experience in clinical development and medical affairs. In particular, he has significant expertise in early clinical development (phases I and II) and has a detailed knowledge of the many steps involved throughout a medicinal products lifecycle (medicinal chemistry, pre-clinical, clinical, marketing, licensing). Although he has worked primarily on biotechnology and medicinal products (including orphan drugs and monoclonal antibodies), his experience includes the development of OTC products and medical devices, and covers a variety of therapeutic indications, with a special emphasis on rare and severe disease (eg in the fields of haematology and oncology).
Prior to joining Voisin Consulting, Jean-Luc has held various senior management positions in the pharmaceutical industry in both Europe and the US. These include Medical Affairs Director at Ipsen, Director of Clinical Operations at Debiopharm International SA, and Vice President, Development at OPi. He also founded the biotechnology company, Karcinolys, which is developing an oncolytic virus against rare and severe cancers, currently at the preclinical stage.
Jean-Luc Béjot holds an MD from X. Bichat Medical School (Paris VII University) and an MBA (International Executive MBA programme) from Georgetown University (Washington, DC, USA).